211 related articles for article (PubMed ID: 22698077)
1. Biomarkers of diabetic nephropathy, the present and the future.
Jim B; Santos J; Spath F; Cijiang He J
Curr Diabetes Rev; 2012 Sep; 8(5):317-28. PubMed ID: 22698077
[TBL] [Abstract][Full Text] [Related]
2. Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy.
Abe H; Sakurai A; Ono H; Hayashi S; Yoshimoto S; Ochi A; Ueda S; Nishimura K; Shibata E; Tamaki M; Kishi F; Kishi S; Murakami T; Nagai K; Doi T
J Med Invest; 2018; 65(3.4):208-215. PubMed ID: 30282862
[TBL] [Abstract][Full Text] [Related]
3. Diabetic nephropathy: traditional to proteomic markers.
Moresco RN; Sangoi MB; De Carvalho JA; Tatsch E; Bochi GV
Clin Chim Acta; 2013 Jun; 421():17-30. PubMed ID: 23485645
[TBL] [Abstract][Full Text] [Related]
4. [Novel biomarkers for diabetic nephropathy].
Araki S
Rinsho Byori; 2014 Feb; 62(2):171-9. PubMed ID: 24800493
[TBL] [Abstract][Full Text] [Related]
5. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
6. Semaphorin3a promotes advanced diabetic nephropathy.
Aggarwal PK; Veron D; Thomas DB; Siegel D; Moeckel G; Kashgarian M; Tufro A
Diabetes; 2015 May; 64(5):1743-59. PubMed ID: 25475434
[TBL] [Abstract][Full Text] [Related]
7. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
8. Identification of nephropathy predictors in urine from children with a recent diagnosis of type 1 diabetes.
Magagnotti C; Zerbini G; Fermo I; Carletti RM; Bonfanti R; Vallone F; Andolfo A
J Proteomics; 2019 Feb; 193():205-216. PubMed ID: 30366120
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy.
Ma J; Chen X; Li JS; Peng L; Wei SY; Zhao SL; Li T; Zhu D; He YX; Wei QJ; Li B
Endocrine; 2015 Jun; 49(2):373-84. PubMed ID: 25424436
[TBL] [Abstract][Full Text] [Related]
10. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria.
Lee SY; Choi ME
Pediatr Nephrol; 2015 Jul; 30(7):1063-75. PubMed ID: 25060761
[TBL] [Abstract][Full Text] [Related]
11. Urinary DcR2 is a novel biomarker for tubulointerstitial injury in patients with diabetic nephropathy.
Chen J; Zhang WW; Chen KH; Lin LR; Dai HZ; Li KL; Zhang JG; Zheng LQ; Fu BQ; He YN
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F273-F281. PubMed ID: 28356293
[TBL] [Abstract][Full Text] [Related]
12. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
13. Urinary podocyte-associated mRNA profile in Egyptian patients with diabetic nephropathy.
Fayed A; Rahman Tohamy IA; Kahla H; Elsayed NM; El Ansary M; Saadi G
Diabetes Metab Syndr; 2019; 13(5):2849-2854. PubMed ID: 31425946
[TBL] [Abstract][Full Text] [Related]
14. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.
Gluhovschi C; Gluhovschi G; Petrica L; Timar R; Velciov S; Ionita I; Kaycsa A; Timar B
J Diabetes Res; 2016; 2016():4626125. PubMed ID: 27413755
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
16. Depletion of Gprc5a Promotes Development of Diabetic Nephropathy.
Ma X; Schwarz A; Sevilla SZ; Levin A; Hultenby K; Wernerson A; Lal M; Patrakka J
J Am Soc Nephrol; 2018 Jun; 29(6):1679-1689. PubMed ID: 29636387
[No Abstract] [Full Text] [Related]
17. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
Qi W; Keenan HA; Li Q; Ishikado A; Kannt A; Sadowski T; Yorek MA; Wu IH; Lockhart S; Coppey LJ; Pfenninger A; Liew CW; Qiang G; Burkart AM; Hastings S; Pober D; Cahill C; Niewczas MA; Israelsen WJ; Tinsley L; Stillman IE; Amenta PS; Feener EP; Vander Heiden MG; Stanton RC; King GL
Nat Med; 2017 Jun; 23(6):753-762. PubMed ID: 28436957
[TBL] [Abstract][Full Text] [Related]
19. PPBP as a marker of diabetic nephropathy podocyte injury via Bioinformatics Analysis.
Zhang F; Jiang N; Gao Y; Fan Z; Li Q; Ke G; Li B; Wu Q; Xu R; Liu S
Biochem Biophys Res Commun; 2021 Nov; 577():165-172. PubMed ID: 34555684
[TBL] [Abstract][Full Text] [Related]
20. In situ assessment of Mindin as a biomarker of podocyte lesions in diabetic nephropathy.
Martins ALMDS; Bernardes AB; Ferreira VA; Wanderley DC; Araújo SA; do Carmo Neto JR; da Silva CA; Lira RCP; Araújo LS; Dos Reis MA; Machado JR
PLoS One; 2023; 18(5):e0284789. PubMed ID: 37130106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
